IceCure Medical shares favorable kidney and breast cancer cryoablation data
IceCure Medical (NASDAQ:ICCM) disclosed positive clinical data evaluating its liquid-nitrogen-based ProSense cryoablation system across multiple tumor indications, showcasing the technology's long-term tumor control and high patient satisfaction metrics.










